PF-04971729CAS号： 1210344-57-2分子式： C22H25ClO7分子量： 436.88描述纯度储存/保存方法别名可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2. |
| 纯度 |
>98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
Ertugliflozin; PF04971729; PF 04971729
|
| 可溶性/溶解性 |
DMSO: ≥ 46 mg/mL
|
| 生物活性 | |
| 靶点 |
hSGLT2
|
| In vitro(体外研究) |
Ertugliflozin (it is claimed) has a 2000-fold increase in selectivity for human SGLT2 over SGLT1 (IC50: SGLT2 = 0.877 nM vs SGLT1 = 1960 nM) in vitro.
|
| In vivo(体内研究) |
Ertugliflozin is rapidly JPorbed in preclinical species after oral administration, and it is characterized by low clearance (excreted in the urine in preclinical species) and a moderate steady-state distribution volume. There is low potential for pharmacokinetic interaction of ertugliflozin. Ertugliflozin is well JPorbed in humans and eliminated largely via glucuronidation. Ertugliflozin improved glycemic control, body weight and blood pressure in patients with T2DM suboptimally controlled by metformin, and is well-tolerated.
|
分子结构图
